Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized estimated eGFR slope of +0.3 (95% CI, -0.4 to 0.9) mL/min/1.73 m²/...
Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and t...
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Sanofi announced that the Europ...
Pharmaceutical marketing is undergoing a significant transformation as companies balance regulatory complexity, digital disruption, evolving workforce ex...
Artificial intelligence is transforming the role of advanced practice providers (APPs) by streamlining documentation, simplifying clinical workfl...
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal...
Demonstrates competitiveness of hyaluronidase-based ADC SC conversion platform Confirms stability of high-concentration ADC SC formulations and improv...
-Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin Am...
Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 rece...
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and c...
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...
A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK...
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
© 2026 Biopharma Boardroom. All Rights Reserved.
